{"url_path":"/sec/imux/8-k/2026-07-14/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000966-index.html","accession_number":"0001193805-26-000966","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000966-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":696,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure**\n\n** **\n\nOn July 14, 2026, Immunic, Inc. a Delaware\ncorporation (the “Company” or “Immunic”)\nmade available an updated presentation (the “Presentation”) on the Company's website.\n\n \n\nThe Presentation is attached as Exhibit 99.1 to\nthis Current Report on Form 8-K, and is incorporated herein by reference.\n\n \n\nThe information in Item 7.01 of this Current Report\non Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities\nAct of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it\nbe deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be\nexpressly set forth therein.\n\n \n\n**Cautionary Note Regarding Forward-Looking\nStatements**\n\n \n\nCertain statements in this Current Report on Form\n8-K and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of\nthe safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical\nfacts, included in this Current Report on Form 8-K, and the Presentation regarding strategy, future operations, future financial position,\nfuture revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials,\nprospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited\nto, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely\nand effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium\nto a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated\nclinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto;\nthe development and commercial potential of any product candidates of the company; Immunic’s continued listing on The Nasdaq Capital\nMarket; and expectations regarding the capitalization, resources and ownership structure of the company and its executive and board structure.\nImmunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking\nstatements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s\ncurrent expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those\nprojected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs\nand macroeconomics trends, impacts of the Ukraine - Russia conflict and the conflict in the Middle East on planned and ongoing clinical\ntrials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future\nliabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational\nrequirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial\nresults, any changes to the size of the target markets for the company’s products or product candidates, the protection and market\nexclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process\nand the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other\nfactors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal\nyear ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies\nof these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this Current Report\non Form 8-K and the Presentation speaks only as of the date of this Current Report on Form 8-K, and the Presentation. Immunic disclaims\nany intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which\nthey were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents\nof this Current Report on Form 8-K and the Presentation."}